154 related articles for article (PubMed ID: 34397694)
41. Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application.
Sun H; Wu YL
Future Oncol; 2019 Aug; 15(23):2769-2777. PubMed ID: 31401844
[TBL] [Abstract][Full Text] [Related]
42. Clinical Value of Upfront Cranial Radiation Therapy in Osimertinib-Treated Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer With Brain Metastases.
Yu F; Ni J; Zeng W; Zhou Y; Guo T; Zeng Y; Zhao Y; Li S; Li Y; Yang X; Zou L; Wang S; Liu Q; Li Y; Chu L; Chu X; Ye L; Yu W; Zhu Z
Int J Radiat Oncol Biol Phys; 2021 Nov; 111(3):804-815. PubMed ID: 34058255
[TBL] [Abstract][Full Text] [Related]
43. Total regression of brain metastases in non-small cell lung cancer patients harboring EGFR mutations treated with gefitinib without radiotherapy: two case reports.
Chonan M; Narita N; Tominaga T
BMC Res Notes; 2016 Jan; 9():2. PubMed ID: 26724810
[TBL] [Abstract][Full Text] [Related]
44. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
[TBL] [Abstract][Full Text] [Related]
45. Radiotherapy for asymptomatic brain metastasis in epidermal growth factor receptor mutant non-small cell lung cancer without prior tyrosine kinase inhibitors treatment: a retrospective clinical study.
Liu S; Qiu B; Chen L; Wang F; Liang Y; Cai P; Zhang L; Chen Z; Liu S; Liu M; Liu H
Radiat Oncol; 2015 May; 10():118. PubMed ID: 26014133
[TBL] [Abstract][Full Text] [Related]
46. Significant efficacy and well safety of apatinib combined with radiotherapy in NSCLC: Case report.
Zhao C; Zhang Q; Qiao W
Medicine (Baltimore); 2017 Dec; 96(50):e9276. PubMed ID: 29390380
[TBL] [Abstract][Full Text] [Related]
47. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
48. A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer.
Lacouture ME; Keefe DM; Sonis S; Jatoi A; Gernhardt D; Wang T; Doherty JP; Giri N; Nadanaciva S; O'Connell J; Sbar E; Piperdi B; Garon EB
Ann Oncol; 2016 Sep; 27(9):1712-8. PubMed ID: 27287210
[TBL] [Abstract][Full Text] [Related]
49. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Mok TS; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Chawla A; Rosell R; Corral J; Migliorino MR; Pluzanski A; Noonan K; Tang Y; Pastel M; Wilner KD; Wu YL
Drugs; 2021 Feb; 81(2):257-266. PubMed ID: 33331989
[TBL] [Abstract][Full Text] [Related]
50. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
51. Effects of dose modifications on the safety and efficacy of dacomitinib for
Corral J; Mok TS; Nakagawa K; Rosell R; Lee KH; Migliorino MR; Pluzanski A; Linke R; Devgan G; Tan W; Quinn S; Wang T; Wu YL
Future Oncol; 2019 Aug; 15(24):2795-2805. PubMed ID: 31313942
[No Abstract] [Full Text] [Related]
52. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.
Zhou Y; Qi X; Wang Y; Dong H; Zhuang L
Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042
[TBL] [Abstract][Full Text] [Related]
53. Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review.
Dong Y; Li Q; Miao Q; Li D
Medicine (Baltimore); 2021 Jun; 100(25):e26450. PubMed ID: 34160440
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer.
Tan W; Giri N; Quinn S; Wilner K; Parivar K
Invest New Drugs; 2020 Jun; 38(3):874-884. PubMed ID: 31858327
[TBL] [Abstract][Full Text] [Related]
55. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
Walia M; Singhal MK; Kamle MS
Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
[TBL] [Abstract][Full Text] [Related]
56. Pilot Study of Dacomitinib for Patients With Metastatic
Choudhury NJ; Makhnin A; Tobi YY; Daly RM; Preeshagul IR; Iqbal AN; Ahn LS; Hayes SA; Heller G; Kris MG; Riely GJ; Yu HA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250398
[TBL] [Abstract][Full Text] [Related]
57. Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
Sepúlveda-Sánchez JM; Vaz MÁ; Balañá C; Gil-Gil M; Reynés G; Gallego Ó; Martínez-García M; Vicente E; Quindós M; Luque R; Ramos A; Ruano Y; Pérez-Segura P; Benavides M; Sánchez-Gómez P; Hernández-Laín A
Neuro Oncol; 2017 Oct; 19(11):1522-1531. PubMed ID: 28575464
[TBL] [Abstract][Full Text] [Related]
58. Management of common adverse events related to first-line dacomitinib use in
Zhou Q; Wu YL; Corral J; Nakagawa K; Garon EB; Sbar EI; Wang T; Sandin R; Noonan K; Gernhardt D; Mok TS
Future Oncol; 2019 May; 15(13):1481-1491. PubMed ID: 30839234
[No Abstract] [Full Text] [Related]
59. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
Zhou S; Ren F; Meng X
Front Immunol; 2022; 13():955944. PubMed ID: 36238280
[TBL] [Abstract][Full Text] [Related]
60. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.
Ahluwalia MS; Becker K; Levy BP
Oncologist; 2018 Oct; 23(10):1199-1209. PubMed ID: 29650684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
